All > Acl > Diet

Serabelisib for PTEN Loss of Function Mutation

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
PTEN Loss of Function Mutation+2 MoreSerabelisib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study if a drug combo is safe and effective with the goal of reducing side effects.

Eligible Conditions
  • Advanced Solid Tumors
  • PIK3CA Gene Mutation
  • PTEN Loss of Function Mutation

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
SQ3370
1
ELVN-001
1
XL114

Study Objectives

11 Primary · 23 Secondary · Reporting Duration: Through study completion, up to 12 months.

Month 8
Cohort 1: Antitumor efficacy of serabelisib in combination with a Study ISD by measuring DCR.
Cohort 1: Antitumor efficacy of serabelisib in combination with a Study ISD by measuring DoR.
Cohort 1: Antitumor efficacy of serabelisib in combination with a Study ISD by measuring ORR.
Cohort 1: Antitumor efficacy of serabelisib in combination with a Study ISD by measuring OS.
Cohort 1: Antitumor efficacy of serabelisib in combination with a Study ISD by measuring PFS.
Cohort 1: Evaluate the compliance of instrasubject modulated dosing for serabelisib in combination with a Study ISD in a pilot cohort.
Cohort 1: Evaluate the pharmacokinetic impact of instrasubject modulated dosing for serabelisib in combination with a Study ISD in a pilot cohort by measuring AUC.
Cohort 1: Evaluate the pharmacokinetic impact of instrasubject modulated dosing for serabelisib in combination with a Study ISD in a pilot cohort by measuring Cmax.
Cohort 1: Evaluate the pharmacokinetic impact of instrasubject modulated dosing for serabelisib in combination with a Study ISD in a pilot cohort by measuring Tmax.
Cohort 1: Evaluate the safety of instrasubject modulated dosing for serabelisib in combination with a Study ISD in a pilot cohort.
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of serabelisib in combination with a Study ISD (Measuring DCR).
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of serabelisib in combination with a Study ISD (Measuring DoR).
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of serabelisib in combination with a Study ISD (Measuring OS).
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of serabelisib in combination with a Study ISD (Measuring PFS).
Cohort 2, 3, 4: Confirm the compliance of serabelisib in combination with a Study ISD.
Cohort 2, 3, 4: Confirm the safety of serabelisib in combination with a Study ISD.
Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.
Month 12
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DCR).
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DoR).
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring OS).
Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring PFS).
Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
Cohort 2, 3, 4: Confirm safety
Cohort 2, 3, 4: Confirm the compliance of study intervention.
Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of efficacy.
Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of toxicity.
Cohorts 1a/1b, 2, 3, 4: Assessment of immune markers in response to study intervention.
Dacryocystorhinostomy
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DoR.
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring ORR.
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring OS.
Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring PFS.
Cohorts 1a/1b: Evaluate compliance
Cohorts 1a/1b: Evaluate safety
Impacted tooth
Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.
Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
SQ3370
1
ELVN-001
1
XL114

Trial Design

6 Treatment Groups

Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid Carcinoma
1 of 6
Cohort 1a - Dose Modification without nab-paclitaxel
1 of 6
Cohort 1b - Dose Modification with Nab-Paclitaxel
1 of 6
Cohort 1 - Dose Modification
1 of 6
Cohort 3 - Expansion Endometrial Cancer
1 of 6
Cohort 2 - Expansion Colorectal Cancer
1 of 6

Experimental Treatment

68 Total Participants · 6 Treatment Groups

Primary Treatment: Serabelisib · No Placebo Group · Phase 1

Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid CarcinomaExperimental Group · 3 Interventions: Insulin Suppressing Diet, Nab paclitaxel, Serabelisib · Intervention Types: Other, Drug, Drug
Cohort 1a - Dose Modification without nab-paclitaxelExperimental Group · 2 Interventions: Insulin Suppressing Diet, Serabelisib · Intervention Types: Other, Drug
Cohort 1b - Dose Modification with Nab-PaclitaxelExperimental Group · 3 Interventions: Insulin Suppressing Diet, Nab paclitaxel, Serabelisib · Intervention Types: Other, Drug, Drug
Cohort 1 - Dose ModificationExperimental Group · 2 Interventions: Insulin Suppressing Diet, Serabelisib · Intervention Types: Other, Drug
Cohort 3 - Expansion Endometrial CancerExperimental Group · 3 Interventions: Insulin Suppressing Diet, Nab paclitaxel, Serabelisib · Intervention Types: Other, Drug, Drug
Cohort 2 - Expansion Colorectal CancerExperimental Group · 2 Interventions: Insulin Suppressing Diet, Serabelisib · Intervention Types: Other, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 12 months.

Who is running the clinical trial?

Faeth TherapeuticsLead Sponsor
2 Previous Clinical Trials
120 Total Patients Enrolled
Vicky MakkerPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
28 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have either a solid tumor or an ovarian cancer with ≥ 50% clear cell histology or ovarian clear cell or ovarian endometrioid carcinoma.
You have a primary ovarian carcinoma.
Cohort 1b - Dose Modification (subjects with solid tumor): failed, were intolerant of, or ineligible for no more than 3 prior lines of therapy (LOT) for advanced/metastatic disease or refused SOC therapy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top